Price and VolumeDetailed Quote
Top NewsMore NewsPerformance
More NewsRead More
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
September 10, 2024
Via Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
September 06, 2024
Via Benzinga
Exposures
Product Safety
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
August 21, 2024
Via Benzinga
Via Benzinga
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
September 05, 2024
Via Benzinga
Via Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
September 04, 2024
Via Benzinga
NASDAQ:BMRN is showing good growth, while it is not too expensive.
September 04, 2024
Via Chartmill
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24
August 24, 2024
Via Talk Markets
Via Benzinga
NASDAQ:BMRN is not too expensive for the growth it is showing.
August 14, 2024
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|